01655nas a2200517   4500000000100000000000100001008004100002260001500043653001800058653002000076653001800096653002500114653002300139100002200162700001800184700001800202700002500220700002300245700003400268700002300302700002000325700001900345700001900364700001400383700001600397700002000413700001900433700001700452700002000469700002200489700001500511700002800526700001600554700001800570700002200588700001800610700001600628700001900644700002400663700002200687245008900709856005500798300000800853520026200861022001401123       2023                            d  c2023-12-2710aAssay systems10aDrug regulation10aLab-on-a-chip10aScientific community10aTissue engineering1 aDavid M. Stresser1 aAnna K. Kopec1 aPhilip Hewitt1 aRhiannon N. Hardwick1 aTerry R. Van Vleet1 aPrathap Kumar S. Mahalingaiah1 aDenice O’Connell1 aGary J. Jenkins1 aRhiannon David1 aJessica Graham1 aDonna Lee1 aJason Ekert1 aAaron Fullerton1 aRemi Villenave1 aPiyush Bajaj1 aJames R. Gosset1 aSherry L. Ralston1 aManti Guha1 aAlejandro Amador-Arjona1 aKainat Khan1 aSaket Agarwal1 aCatrin Hasselgren1 aXiaoting Wang1 aKhary Adams1 aGaurav Kaushik1 aArkadiusz Raczynski1 aKimberly A. Homan00aTowards in vitro models for reducing or replacing the use of animals in drug testing  uhttps://www.nature.com/articles/s41551-023-01154-7  a1-63 aPharmaceutical companies continue to advocate for the use of in vitro models towards the reduction of animal use in drug discovery and development while acknowledging that further advancements are needed to heighten the models’ current state of readiness.  a2157-846X